| Clinical management and current research in isolated limb perfusion for sarcoma and melanoma. | |
| | |
MedLine Citation:
|
PMID: 9499194 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Currently, isolated limb perfusion (ILP) attracts major interest in the treatment of soft tissue sarcoma and melanoma confined to the limb. The procedure combines innovative approaches such as hyperthermia, the use of cytokines, as well as the administration of high-dose chemotherapy. Although used since more than 40 years, the basic knowledge on the mode of action of ILP is still limited. Besides regional toxicity, systemic effects following the application of rhTNF in the perfusion circuit have to be taken into account. Furthermore, WHO criteria of tumor response are rarely met after perfusion of sarcomas. To overcome this, new modalities based on tumor metabolism are currently under investigation. Also the clinical decision on how to proceed after a successful ILP is discussed. |
| | |
Authors:
|
P Hohenberger; C Kettelhack |
Related Documents
:
|
2487144 - Molecular differential pathology of rhabdomyosarcoma. 12736494 - Diagnostic significance and clinical applications of chimeric genes in ewing's sarcoma. 9777984 - Intramuscular myxoma: a clinicopathologic study of 51 cases with emphasis on hypercellu... 6297234 - Hepatocellular carcinoma combined with hepatic mesenchymal cell tumor and sarcoma. 333864 - The relationship between age-dependent immunological competence of host and tumor growt... 9370974 - Cell death during luteal regression in the marmoset monkey (callithrix jacchus). |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Oncology Volume: 55 ISSN: 0030-2414 ISO Abbreviation: Oncology Publication Date: 1998 Mar-Apr |
Date Detail:
|
Created Date: 1998-03-09 Completed Date: 1998-03-09 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 0135054 Medline TA: Oncology Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 89-102 Citation Subset: IM |
Affiliation:
|
Max Delbrück Center for Molecular Medicine, Virchow Klinikum, Humboldt University, Berlin, Germany. hohenberger@rrk-berlin.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Agents
/
administration & dosage* Body Temperature Cytokines / physiology, therapeutic use* Extremities* Humans Hyperthermia, Induced* Melanoma / therapy* Perfusion / methods* Sarcoma / therapy* Survival Analysis Treatment Outcome Tumor Necrosis Factor-alpha / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Cytokines; 0/Tumor Necrosis Factor-alpha |
| Comments/Corrections | |
Erratum In:
|
Oncology 1998 Jul-Aug;55(4):344 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hemolytic uremic syndrome in prostatic carcinoma.
Next Document: Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases.